JUL 24, 2019 10:40 PM PDT

HIV Therapeutics Places Risk of Neural Tube Defects

WRITTEN BY: Nouran Amin

In a study published in the New England Journal of Medicine, women taking an HIV therapeutic drug containing dolutegravir have a higher risk of giving birth to children with neural tube defects particularly in comparison to women taking other antiretroviral drug regimens.

Learn more on neural tube defects:

Neural tube defects consist of abnormalities in the development of the brain and spinal column. The NICHD-funded study, which began in 2014 in Botswana, was used to track birth outcomes, including neural tube defects for infants born to women taking antiretroviral therapy for an HIV infection in eight hospitals.

Upon findings, Botswana changed their treatment guidelines to recommend drug combinations containing dolutegravir for all adults, this included pregnant women. However, later preliminary studies indicated a potential risk between mothers receiving the drug and neural tube defects among their infants—this is especially true for women who received the dolutegravir treatment around the time they conceived.

During the International AIDS Society Conference, researchers reported their findings describing women that were on dolutegravir since conception. Of these women, five neural tube defects occurred out of 1,683 births (0.3%). However, women who were on the drug, efavirenz, since conception had three cases of neural tube defects out of 7,959 births (0.04%). Furthermore, women receiving another HIV treatment regimens that did not involve dolutegravir had 15 neural tube defect cases out of 14,792 births (0.1%). At the end, the findings concluded 0.2% difference in risk for infants born to women on dolutegravir drug therapy since conceiving. Although the risk is small, findings are significant.

Source: National Institute of Health

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
DEC 30, 2020
Cannabis Sciences
Cannabis Reduces Stress and Anxiety in Over 95% of Cases
DEC 30, 2020
Cannabis Reduces Stress and Anxiety in Over 95% of Cases
Whether cannabis will induce feelings of relaxation or anxiety often feels like a coin toss. Now, however, researchers f ...
FEB 26, 2021
Microbiology
Good Bacteria Fights Bad Bacteria in a Clinical Trial
FEB 26, 2021
Good Bacteria Fights Bad Bacteria in a Clinical Trial
Eczema is a skin condition that causes a chronic, itchy rash. The most common form of the disorder, atopic dermatitis, i ...
FEB 24, 2021
Drug Discovery & Development
Novel Neurofeedback Technique Improves Symptoms of Depression and Psychosis
FEB 24, 2021
Novel Neurofeedback Technique Improves Symptoms of Depression and Psychosis
Researchers from the University of Rochester have found that real-time functional magnetic resonance imaging (fMRI) neur ...
MAR 06, 2021
Genetics & Genomics
Green Tea Extract Can Affect Facial Development in Kids With Down Syndrome
MAR 06, 2021
Green Tea Extract Can Affect Facial Development in Kids With Down Syndrome
Individuals with Down syndrome often have certain facial features. New research has suggested that green tea supplements ...
APR 13, 2021
Immunology
The "Unexpected" Reason Why COVID Antivirals Don't Work
APR 13, 2021
The "Unexpected" Reason Why COVID Antivirals Don't Work
Purdue University researchers have made a breakthrough finding that could explain why the disease is so hard to manage t ...
APR 14, 2021
Cancer
Cell Viability- Where to Begin?
APR 14, 2021
Cell Viability- Where to Begin?
Written By: Author As I pondered the title of this article, my thoughts immediately went back to a request by my Ph.D. a ...
Loading Comments...